Literature DB >> 9635604

Giant gastric ulcers and risk factors for gastroduodenal mucosal disease in orthotopic lung transplant patients.

D A Lipson1, J A Berlin, H I Palevsky, R M Kotloff, G Tino, J Bavaria, L Kaiser, W B Long, D C Metz, G R Lichtenstein.   

Abstract

Giant gastric ulcers are defined as ulcers with a diameter greater than 3 cm. Previously they have not been described in lung transplant recipients. We report a high incidence of symptomatic giant gastric ulcers and identify the risk factors for ulcer development in these patients. We examined the records of all 95 patients who had undergone lung transplantation at our institution from November 1991 to July 1995. Fourteen of the patients who underwent lung transplantation developed symptoms that required esophagogastroduodenoscopy. Three of these patients (21%) were found to have giant gastric ulcers. The relative risk of giant gastric ulcer in symptomatic patients undergoing endoscopy after lung transplantation is over 40 times that of population controls. The patients who developed giant gastric ulcers, despite H2 antagonist use, had all received bilateral lung transplantation and had received nonsteroidal antiinflammatory drugs, cyclosporine, and high-dose intravenous corticosteroids. The risk of developing giant gastric ulcers is significantly increased in patients who have undergone bilateral orthotopic lung transplantation. Clinicians should be made aware of this complication in order to avoid use of ulcerogenic medications in this population. Avoidance of these medications could potentially minimize the risk of this complication.

Entities:  

Mesh:

Year:  1998        PMID: 9635604     DOI: 10.1023/a:1018835219474

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  35 in total

1.  An endoscopic evaluation of the effects of non-steroidal anti-inflammatory drugs on the gastric mucosa.

Authors:  F Lanza; G Royer; R Nelson
Journal:  Gastrointest Endosc       Date:  1975-02       Impact factor: 9.427

Review 2.  Nonassociation of adrenocorticosteroid therapy and peptic ulcer.

Authors:  H O Conn; B L Blitzer
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

3.  Peptic ulcer disease following renal transplantation.

Authors:  S J Knechtle; K Kempf; R R Bollinger
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

4.  Clinically important interaction of cyclosporine and erythromycin.

Authors:  B M Murray; L Edwards; G D Morse; R R Kohli; R C Venuto
Journal:  Transplantation       Date:  1987-04       Impact factor: 4.939

5.  Benign giant gastric ulcer.

Authors:  D J Lulu
Journal:  Am Surg       Date:  1971-06       Impact factor: 0.688

6.  Short-term high-dose corticosteroids and gastroduodenal mucosa. A prospective clinical study on renal transplant recipients.

Authors:  H Paimela; K Höckerstedt; H von Numers; J Ahonen
Journal:  Transpl Int       Date:  1990-07       Impact factor: 3.782

Review 7.  Management of gastroduodenopathy associated with use of nonsteroidal anti-inflammatory drugs.

Authors:  D S Loeb; D A Ahlquist; N J Talley
Journal:  Mayo Clin Proc       Date:  1992-04       Impact factor: 7.616

8.  Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era.

Authors:  C Troppmann; B E Papalois; A Chiou; E Benedetti; D L Dunn; A J Matas; J S Najarian; R W Gruessner
Journal:  J Am Coll Surg       Date:  1995-04       Impact factor: 6.113

9.  Upper gastrointestinal dysmotility in heart-lung transplant recipients.

Authors:  J Au; T Hawkins; C Venables; G Morritt; C D Scott; A D Gascoigne; P A Corris; C J Hilton; J H Dark
Journal:  Ann Thorac Surg       Date:  1993-01       Impact factor: 4.330

Review 10.  Ulcers, nonsteroidal antiinflammatory drugs, and related matters.

Authors:  A H Soll; J Kurata; J E McGuigan
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

View more
  1 in total

1.  Recipient Comorbidities for Prediction of Primary Graft Dysfunction, Chronic Allograft Dysfunction and Survival After Lung Transplantation.

Authors:  Jonas Peter Ehrsam; Macé M Schuurmans; Mirjam Laager; Isabelle Opitz; Ilhan Inci
Journal:  Transpl Int       Date:  2022-06-29       Impact factor: 3.842

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.